Watch the Webcast The Annual General Meeting was streamed live. To access the webcast, please use the link below:Watch the Webcast Please click on the links below for information concerning Genmab A/S’ Annual General Meeting 2026.Shareholder letterNotice of Annual General Meeting 2026 with agenda, including Appendix 1: Candidates for the Board of DirectorsRegister online or use the registration formSubmit proxy or postal vote online or use the form to submit proxy or postal vote2025 Annual Report of Genmab A/S2025 Compensation Report2025 Danish SummaryThe total number of voting rights and total share capital per February 18, 2026, is:Total Number of Voting Rights: 64,238,408Total Share Capital: 64,238,408Questions regarding registration to participate may be directed to Euronext Securities at tel. no. (+45) 43 58 88 66 or CPH-investor@euronext.com. We process your personal data in accordance with applicable rules. Please click here to read our Privacy Policy.Please note that Genmab A/S, as a general rule, no longer sends the calling to Annual General Meetings by postal mail. If you wish to receive the invitation to future Annual General Meetings via e-mail, please register your e-mail address at the InvestorPortal. If you do not have access to an e-mail address, please contact Euronext Securities at: +45 4358 8866. Contact Investor Relations Our aim is to deliver reliable and transparent information to our shareholders. If you have questions about Genmab, our products or other relevant shareholder information, please use the information below to contact us. We will handle your personal data in accordance with our Privacy Policy. Image Andrew Carlsen Vice President, Head of Investor Relations Email acn@genmab.com Telephone +45 3377 9558 Address Carl Jacobsens Vej 302500 ValbyDenmark For general Investor Relations Inquiries please contact ir@genmab.com.